Ensysce Biosciences Inc. (NASDAQ: ENSC) shares rallied 58.66% to close at $0.63 on Friday following the company's announcement of a comprehensive strategic review process. The board of directors has initiated an evaluation of potential alternatives, including partnership opportunities, licensing agreements, and asset sales, with the stated objective of maximizing shareholder value.
The strategic review centers on the company's proprietary TAAP (Tamper Resistant And Abuse Protective) and MPAR (Multi-Pill Abuse Resistant) technologies, which are designed to address safety concerns associated with opioid medications. These platforms represent the core intellectual property assets of the pain-focused biotech firm as it seeks to identify optimal paths forward for their development and commercialization.
The announcement marks a significant development for the company, which specializes in developing abuse-resistant formulations of FDA-approved opioid medications. By exploring multiple strategic options, Ensysce's board has signaled its commitment to evaluating various avenues that could unlock value for shareholders while advancing its mission to develop safer pain management solutions.